Structure Therapeutics (GPCR) has been in focus after encouraging Phase 2 results for its lead obesity drug candidate, aleniglipron, as well as a new licensing deal with Genentech covering patents tied to CT-996.

Those aleniglipron Phase 2 results and the Genentech licensing deal have arrived after a strong run, with a 90 day share price return of 127.71% and a 1 year total shareholder return of 172.69%, suggesting momentum has recently been building.

If obesity drug data has caught your attention, this could be a good moment to scan other healthcare stocks that might fit a similar thesis.

With the share price already up sharply and the last close at US$68.61 versus an average analyst price target of US$101.79, you have to ask yourself: is there still a genuine opportunity here, or is the market already pricing in the next leg of growth?

Price to Book of 6.2x: Is it justified?

At a P/B of 6.2x versus a last close of US$68.61, Structure Therapeutics trades at a richer level than many peers, which sets a high bar for future execution.

The P/B ratio compares the company’s market value to its book value, which is essentially net assets on the balance sheet. For a clinical stage biopharma with no meaningful revenue and ongoing losses, P/B often acts as a shorthand for how much investors are willing to pay today for the pipeline and future potential.

GPCR is flagged as good value when measured against a peer average P/B of 7.3x, implying the market is not assigning the highest premium available within its comparison set. At the same time, the stock is described as expensive relative to the broader US Pharmaceuticals industry, where the average P/B is 2.6x, which is less than half GPCR’s current multiple.

That gap to the wider industry is substantial, and it shows investors are pricing Structure Therapeutics closer to a high expectation peer group than to the typical pharma name.

Result: Price-to-book of 6.2x (ABOUT RIGHT)

However, you still have to weigh typical biotech risks, including clinical or regulatory setbacks for obesity candidates and ongoing net losses of US$210.685 million.

Build Your Own Structure Therapeutics Narrative

If you see the numbers differently, or prefer to stress test the assumptions yourself, you can rebuild the story in a few minutes: Do it your way.

A great starting point for your Structure Therapeutics research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you like what you see here, do not stop at a single stock, use the Simply Wall St screener to hunt for other opportunities that match your style.

• Target reliable income by scanning these 12 dividend stocks with yields > 3% that already offer yields above 3% and might suit a long term cash flow focus.
• Chase growth themes by checking out these 28 AI penny stocks tied to artificial intelligence, where business models often sit at the front of emerging trends.
• Spot potential value by reviewing these 882 undervalued stocks based on cash flows that our models flag as trading below their estimated cash flow based worth.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.